There are currently 33 active clinical trials seeking participants for Acute Kidney Injury research studies. The states with the highest number of trials for Acute Kidney Injury participants are California, Ontario, Texas and New York.
A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)
Recruiting
The aim of this study is to evaluate the efficacy and safety of GDC-8264 compared with placebo in participants undergoing cardiac surgery who are determined to be at moderate to high risk of developing AKI and subsequent MAKE at 90 days after surgery (MAKE90). The study will be performed in two parts- Part 1 and Part 2.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/28/2025
Locations: Ronald Reagan UCLA Medical Center, Los Angeles, California +30 locations
Conditions: Acute Kidney Injury
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
Recruiting
Patients with renal insufficiency who undergo cardiac surgery with cardiopulmonary bypass (CPB) are at significant risk for exacerbation of renal dysfunction postoperatively. This in turn is associated with an increased risk of prolonged intensive care unit (ICU) length of stay, other comorbidities including surgical complications and 30-day mortality. Renal impairment is generally identified based on an increase in serum creatinine concentration and/or a certain magnitude decrease in estimated... Read More
Gender:
ALL
Ages:
Between 22 years and 85 years
Trial Updated:
07/25/2025
Locations: Cleveland Clinic Florida, Weston, Florida
Conditions: Renal Impairment After Cardiac Surgery, Renal Impairment, Acute Kidney Injury
KIDney Injury in Times of COVID-19 (KIDCOV)
Recruiting
There is an unmet need to evaluate the impact of sub-clinical/mild COVID19 disease in the outpatient setting on prevalent and incident renal injury, as this data is currently unavailable. To capture the diversity of race/ethnic risk and COVID19 related municipal shelter-in-place guidance, the investigators will enroll COVID19-negative and COVID19-positive samples balanced by race/ethnicity from 3 different states, California, Michigan, and Illinois. Study endpoints will be assayed from urine sam... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: UCSF, San Francisco, California +2 locations
Conditions: SARS-CoV Infection, Covid19, Corona Virus Infection, Acute Kidney Injury, Kidney Injury
Clinical Validation of the RENISCHEM L-FABP POC Assay
Recruiting
This study will involve measurement of levels of a novel urinary biomarker of renal ischemia, L-FABP. The purpose of the study is to perform a clinical validation of the ability of L-FABP measurements in urine using the RENISCHEM L-FABP POC Test to predict the development of AKI within 2 days following cardiac and vascular catheterization procedures involving exposure to radiocontrast media.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Chandler Regional Medical Center, Chandler, Arizona +5 locations
Conditions: Acute Kidney Injury, Contrast-induced Nephropathy
Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury
Recruiting
This randomized, controlled, pivotal study is intended to determine whether up to ten sequential 24-hour treatments with the Selective Cytopheretic Device (SCD) will improve survival in patients with Acute Kidney Injury (AKI) requiring continuous kidney replacement therapy (CKRT) when compared to CKRT alone (standard of care). This study is further intended to determine whether SCD therapy will reduce the duration of maintenance dialysis secondary to AKI. This study will enroll approximately 200... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: University of Alabama Birmingham Hospital, Birmingham, Alabama +29 locations
Conditions: Acute Kidney Injury
CTSN Embolic Protection Trial
Recruiting
This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/15/2025
Locations: CHI St. Vincent Heart Institute, North Little Rock, Arkansas +27 locations
Conditions: Delirium, Ischemic Stroke, Acute Kidney Injury, Heart Valve Disease, Coronary Artery Disease
QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry
Recruiting
QUELIMMUNE is FDA-approved under an HDE for the treatment of pediatric patients (weight ≥10kg and age ≤22 years) with AKI due to sepsis or a septic condition on antibiotic therapy and requiring RRT. The purpose of this surveillance registry is to prospectively collect safety data among all patients treated with QUELIMMUNE under the HDE. More specifically, we intend on comparing the incidence of new (secondary) blood stream infections in the first 28 days after SCD-PED initiation to a comparator... Read More
Gender:
ALL
Ages:
22 years and below
Trial Updated:
07/12/2025
Locations: Children's of Alabama, Birmingham, Alabama +7 locations
Conditions: Acute Kidney Injury, Acute Kidney Injury Due to Sepsis
Initial Resuscitation for Acute Kidney Injury in Cirrhosis
Recruiting
The goal of this interventional study is to evaluate two strategies for how to provide intravenous (IV) fluids for treating patients with acute kidney injury (AKI) in cirrhosis. The main question it aims to answer is: what is the safety, efficacy, and feasibility of providing a recommendation to use a Volume Assessment Guidance Algorithm (VAGA) or give standard of care doses of IV albumin? Patients will be randomly assigned where their treating teams will receive a VAGA-based recommendation or... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Cirrhosis, Liver, Acute Kidney Injury, Hepatorenal Syndrome
A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"
Recruiting
Approximately 150 patients with acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF) will be randomized at up to 40 sites. Patients will be randomly assigned to either Auxora or matching placebo. Study drug infusions will occur every 24 hours for five consecutive days for a total of five infusions.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: University of Alabama, Birmingham, Alabama +36 locations
Conditions: Acute Kidney Injury
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
Recruiting
This study tests whether a medication called droxidopa can help improve blood flow to the kidneys in people with liver cirrhosis who develop kidney problems while in the hospital. When someone with cirrhosis experiences kidney injury, having better blood pressure can help their kidneys recover. Droxidopa is an oral medication that may help raise blood pressure without requiring intensive care or invasive treatments. The study will compare droxidopa to a placebo (inactive pill) in 75 people hospi... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/03/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Acute Kidney Injury, Cirrhosis, Decompensated Cirrhosis of Liver
Optimizing Pulsatility During Cardiopulmonary Bypass to Reduce Acute Kidney Injury
Recruiting
The objective is to determine the effectiveness of pulsatile flow during cardiopulmonary bypass to reduce the incidence of acute kidney injury after cardiac surgery. Investigators will also evaluate the safety and impact of pulsatile flow on clinical outcomes compared to non-pulsatile flow during cardiopulmonary bypass.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/19/2025
Locations: University of Colorado Hospital, Aurora, Colorado
Conditions: Acute Kidney Injury, Hemolysis, Thrombocytopenia, Surgery
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)
Recruiting
The central hypothesis of this research study is that perioperative administration of the proton pump inhibitor (PPI) pantoprazole could reduce the development of acute kidney injury (AKI) following cardiac surgery by activation molecular pathways for kidney protection. The investigators propose a single-center, randomized, controlled, single-blinded trial to determine whether perioperative intravenous administration of pantoprazole will reduce the incidence of AKI, some molecules that can be de... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/09/2025
Locations: Memorial Hermann Texas Medical Center, Houston, Texas
Conditions: Acute Kidney Injury